<DOC>
	<DOCNO>NCT02873351</DOCNO>
	<brief_summary>From 3 large patient database , patient diagnose AMD never take levodopa ( L-DOPA ) contain medication mean age diagnosis 71 year . Patients treat L-DOPA contain medication mean age diagnosis AMD 79 year . L-DOPA bind GPR143 retinal pigment epithelium , release PEDF , protect retina downregulates VEGF , cause neovascularization . The Investigators evaluate safety tolerability carbidopa-levodopa patient AMD , measure effect surrogate functional biomarkers AMD .</brief_summary>
	<brief_title>A Safety Efficacy Study Carbidopa-levodopa Patients With Macular Degeneration</brief_title>
	<detailed_description>Age-related macular degeneration ( AMD ) common cause blindness , individual age 50 , develop world ( 1,2 ) . AMD become common people age , common lightly pigment individual ( 3 ) . AMD appear common patient Parkinson 's Disease , without ( 4 ) . The AREDS nutritional supplement effective slow progress intermediate AMD ( 5 ) . Most AMD `` dry AMD '' , progress relatively slowly may impair vision , usually lead legal blindness . There two form AMD , `` wet AMD '' geographic atrophy ( GA ) , cause profound vision loss . In aggregate occur 25 % patient AMD ( 5 ) . Wet AMD due new growth abnormal blood vessel retina . The new blood vessel believe due excessive release vascular endothelial growth factor ( VEGF ) retinal pigment epithelium ( RPE ) cell ( 6 ) . Wet AMD effectively treat intraocular injection VEGF inhibitor ( 2 ) . Geographic Atrophy , form advance AMD , represent focal death RPE cell overlie neurosensory retina . There current treatment GA . It suspect GA due part localize inflammatory response , damage RPE cell loss RPE cell function ( 7 ) . It may also speculate stimulation RPE cell release potent neurotrophic factor , pigment epithelium derive factor ( PEDF ) may slow progression GA . In 2008 , Dr. Brian McKay identify receptor , G protein couple receptor # 143 ( GPR143 ) , surface RPE cell discover L-DOPA natural ligand stimulator GPR143 ( 8 ) . Dr McKay show treatment RPE cell exogenous L-DOPA result release additional PEDF . In subsequent work Dr McKay 's group also show L-DOPA stimulation PEDF RPE cell also associate decrease VEGF ( 9 ) . Thus , Dr McKay hypothesize exogenous L-DOPA may prevent onset AMD progression wet AMD . In 2015 , Dr McKay associate publish paper show patient , treat L-DOPA , delay onset AMD 8 year , compare patient treat L-DOPA ( 10 ) . In addition , AMD go develop wet AMD , 5 year later history L-DOPA treatment ( 10 ) . L-DOPA intermediate pigmentation pathway . Dr McKay associate suggest reason darkly pigment race get AMD nearly frequently light pigmented race , produce pigment , thus L-DOPA stimulate GPR143 RPE cell . According hypothesis , stimulate RPE cell release PEDF decrease VEGF , together responsible protective effect . Since establish animal model AMD , L-DOPA good safety profile healthy volunteer patient Parkinson 's disease ( 11 ) , Investigators propose prospective experiment determine safety tolerability L-DOPA , population patient AMD . The participant make aware potential side effect L-DOPA , list Informed Consent , consent process . Adverse event elicit question participant visit . The participant also advise call site , medical problem visit . The Investigators also use safety study examine whether L-DOPA positive effect surrogate biomarkers AMD . The surrogate marker evaluate dark adaptation ( 12,13 ) , best correct visual acuity ( BCVA ) , low luminance visual acuity ( LLVA ) ( 14 ) , size number drusen ( 15 ) reticular pseudodrusen ( 16 ) . A previous trial , retinol 104 patient , significantly improve dark adaptation 30 day . ( 17 ) Therefore , Investigators expect see improvement L-DOPA relatively short time . This study also help Investigators prepare Phase 3 study L-DOPA AMD . Pharmacology L-DOPA carbidopa L-DOPA form 3-hydroxylation tyrosine tyrosine-3-monooxygenase ( tyrosinase ) . ( 18 ) The primary metabolic pathway L-DOPA decarboxylation amino acid decarboxylase dopamine , responsible , , pharmacologic effect toxicity . When carbidopa administer L-DOPA , systemic level L-DOPA double central nervous system ( CNS ) L-DOPA increase 1 % administer dose 4 % . Levodopa freely pass systemic circulation retina brain , dopamine carbidopa . Adverse event markedly decrease carbidopa administer L-DOPA , systemic level toxic metabolite L-DOPA , dopamine , markedly reduce . In patient , 25 mg carbidopa sufficient control side effect 100 mg L-DOPA , primarily nausea ( 18 ) , 90 % . However , patient require additional supplemental carbidopa . Carbidopa limit side effect give alone ( 18 ) . Therefore , Investigators plan use 35 mg carbidopa 100 mg levodopa , order control adverse event almost participant . L-DOPA natural ligand GPR143 RPE cell ( 8 ) . The Investigators ' intent increase L-DOPA available RPE surface receptor ( GPR 143 ) minimize peripheral toxicity . This concept unique , use L-DOPA rely CNS conversion L-DOPA dopamine , order produce desire effect ( 19 ) . Treatments : 1 . Carbidopa-levodopa 35-100 mg dose hs 45 day , follow carbidopa-levodopa 35-100 mg dose morning , supper h 45 day . The second dosing period equivalent moderate dose carbidopa-levodopa patient Parkinson 's disease ( maximum daily dose 200-800 mg ) . 2 . Placebo dose hs 45 day , follow placebo dose morning , supper h 45 day . Placebo active medication dose capsule , identical appearance . Number participant : Not yet recruit , stratify non-study eye normal , dry AMD wet AMD randomize use table random number . Estimated screen failure rate 50 % . The sample size base successful study treat patient impaired dark adaptation retinol , show significant improvement 30 day 52 patient per study arm . Duration : 87-114 day ( 80-100 day treatment ) . Visits 1 ( screen ) 2 ( randomization ) schedule within 1 week . The first visit Randomization , Visit 3 , occur 40-50 day Visit 2 . Visit 4 ( end study ) occur 40-50 day Visit 3 . This schedule allow 10 day window study visit , logistic reason patient convenience . Overall trial duration enrollment treatment , screen 5 patient per week , approximately 10 month . Primary Endpoint : A statistically significant improvement carbidopa-levodopa treatment : dark adaptation ; BCVA ; LLVA ; drusen reticular pseudodrusen measure spectral domain ( SD ) optical coherence tomography ( OCT ) Measurements : 1 . Demographics Visit 1 ; 2 . Medical History Physical Examination Visit 1 ; 3 . Electrocardiogram ( ECG ) , complete blood count ( CBC ) , Chem 20 HbA1C Visit 1 ; 4 . Vital sign Visits 1,3,4,5 6 ; 5 . Non-directed assessment adverse event Visits 1,2 , 3 4 ; 6 . Ophthalmic history comprehensive eye examination , include dark adaptation SD OCT Visit 2 ( Baseline ) ; 7 . Low luminance questionnaire visit 2 , 3 4 ; 8 . Pill count Visits 3 4 ; 9 . Re-measurement dark adaptation , visual acuity normal low light condition SD OCT Visits 3 4 ( End Study ) ; Statistics : Analysis Variance Independent Variables : 1 . Active Drug v Placebo ; 2 . Logarithm daily dose active drug ; 3 . Duration treatment ( measurement Visits 3 , 4 , 5 6 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>1 . A diagnosis intermediate advance dry AMD least one eye . The eye may normal stage AMD . If participant take AREDS vitamin supplement , supplement must continue duration study . If participant take AREDS vitamin supplement , supplement must start study . 2 . Any previous prescription LDOPA dopamine agonist medication , plan use agent , except study medication , study ; Concurrent use monoamine oxidase ( MAO ) inhibitor ; With exception AMD cataract previous cataract operation ; eye condition , disease , history surgery , trauma either eye , impair vision ; Neurologic condition impair vision ; Parkinson 's Disease ; Dark adaptation rod intercept &lt; 6.5 minute ; Significant orthostatic hypotension , define drop systolic blood pressure , immediately upon change supine stand position , &gt; 19 mmHg , symptomatic drop systolic blood pressure , immediately upon change supine stand position ; Significant ECG abnormality , judge Investigator ; Estimated glomerular filtration rate ( eGFR ) &lt; 30 ml/min ; Liver enzymes &gt; 3 X upper limit normal ; HbA1C &gt; 9.0 ; Any significant lab abnormality , judge Investigator . Women childbearing potential ; Subjects fluent English .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>L-DOPA</keyword>
	<keyword>GPR143</keyword>
	<keyword>PEDF</keyword>
	<keyword>VEGF</keyword>
</DOC>